Calgary, Alberta -  TheNewswire - September 12, 2022 -  Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that its common shares have commenced trading on the OTC QB Market under the symbol "OTCFF". The Company's common shares will continue to trade on the TSX Venture Exchange under the symbol “OTC” and the Frankfurt Stock Exchange under the symbol “2QBO”.

The Company has listed on the OTC QB Market to facilitate greater trading visibility and convenience for US-based investors, resulting in more liquidity and greater reach.

“The rapid development of our adaptive intraocular lens technology has caused many US investors to ask us to obtain a US listing to allow them to purchase Ocumetics stock,” says Dr. Mark Lee, CEO of Ocumetics.

“We are pleased to complete this listing and look forward to increasing our base of US investors and sharing development progress of our accommodating intraocular lens with this group,” adds Dr. Lee.  

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that specializes in adaptive lens designs.  Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.  

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. Mark Lee

President and CEO

(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.